Bosentan and the endothelin system in congestive heart failure.
The endothelin system appears to play an important role in the pathophysiology of congestive heart failure (CHF). Endothelin receptor antagonists represent a novel class of agents that are being evaluated for their potential benefits in treating various cardiovascular disorders. Bosentan is an orally active endothelin receptor antagonist that has been studied for the treatment of CHF. Early clinical experience with bosentan has confirmed some benefits on hemodynamic parameters in patients with CHF. Its role in slowing the progression of the disease and improving survival remains to be elucidated.
Ellahham
S H
SH
Division of Cardiology, Washington Hospital Center, DC 20010, USA.
Charlon
V
V
Abassi
Z
Z
Calis
K A
KA
Choucair
W K
WK
D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000077300:Bosentan; D018849:Controlled Clinical Trials as Topic; D004285:Dogs; D004311:Double-Blind Method; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000502:physiology; D016232:Endothelins / Q000502:physiology; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics; D006801:Humans; D010919:Placebos; D051381:Rats; D017466:Receptors, Endothelin / Q000502:physiology; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D016232:Endothelins; D010919:Placebos; D017466:Receptors, Endothelin; D013449:Sulfonamides; D000077300:Bosentan